Relaxin-3 receptor (Rxfp3) gene knockout mice display reduced running wheel activity: Implications for role of relaxin-3/RXFP3 signalling in sustained arousal

Behavioural Brain Research

Volumn 278, Issue , 2015, Pages 167-175

  Hosken, Ihaia T ^a,b   Sutton, Steven W ^c   Smith, Craig M ^a,b   Gundlach, Andrew L ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Arousal; Neuropeptide receptor; Relaxin 3; Running wheel activity; RXFP3

Indexed keywords

NEUROPEPTIDE RECEPTOR; RELAXIN 3; RELAXIN 3 RECEPTOR; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; RELAXIN; RELAXIN-3 PROTEIN, MOUSE; SALPR PROTEIN, MOUSE;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; AROUSAL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; FORCED SWIM TEST; GENE INACTIVATION; GENOTYPE; HYPOACTIVITY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; PHENOTYPE; PREPULSE INHIBITION; PROTEIN FUNCTION; ROTAROD TEST; RUNNING WHEEL ACTIVITY; SENSORY GATING; SEX DIFFERENCE; SPATIAL MEMORY; SPATIAL MEMORY TEST; STARTLE REFLEX; TRANSGENIC MOUSE; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENETICS; MAZE TEST; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; RECOGNITION; SIGNAL TRANSDUCTION; VISUAL ADAPTATION;

ADAPTATION, OCULAR; ANALYSIS OF VARIANCE; ANIMALS; AROUSAL; EXPLORATORY BEHAVIOR; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PREPULSE INHIBITION; RECEPTORS, G-PROTEIN-COUPLED; RECOGNITION (PSYCHOLOGY); REFLEX, STARTLE; RELAXIN; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION;

EID: 84908689027     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.09.028     Document Type: Article

References (67)

1. Bathgate R.A.D., Samuel C.S., Burazin T.C.D., Layfield S., Claasz A.A., Reytomas I.G., et al. Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. Novel members of the relaxin peptide family. J Biol Chem 2002, 277:1148-1157.
2. Burazin T.C.D., Bathgate R.A.D., Macris M., Layfield S., Gundlach A.L., Tregear G.W. Restricted, but abundant, expression of the novel rat gene-3 (R3) relaxin in the dorsal tegmental region of brain. J Neurochem 2002, 82:1553-1557.
3. Ma S., Gundlach A.L. Relaxin-family peptide and receptor systems in brain: insights from recent anatomical and functional studies. Adv Exp Med Biol 2007, 612:119-137.
4. Tanaka M. Relaxin-3/insulin-like peptide 7, a neuropeptide involved in the stress response and food intake. FEBS J 2010, 277:4990-4997.
5. Smith C.M., Ryan P.J., Hosken I.T., Ma S., Gundlach A.L. Relaxin-3 systems in the brain - the first 10 years. J Chem Neuroanat 2011, 42:262-275.
6. Bathgate R.A.D., Halls M.L., van der Westhuizen E.T., Callander G.E., Kocan M., Summers R.J. Relaxin family peptides and their receptors. Physiol Rev 2013, 93:405-480.
7. Ganella D.E., Ma S., Gundlach A.L. Relaxin-3/RXFP3 signaling and neuroendocrine function - a perspective on extrinsic hypothalamic control. Front Endocrinol (Lausanne) 2013, 4:128.
8. Ryan P.J., Kastman H.E., Krstrew E.V., Chirlov L., Rosengren K.J., Hossain M.A., et al. Relaxin-3/RXFP3 system regulates alcohol-seeking. Proc Natl Acad Sci U S A 2013, 110:20789-20794.
9. Smith C.M., Walker A.W., Hosken I.T., Chua B.E., Zhang C., Haidar M., et al. Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?. Front Pharmacol 2014, 5:A46.
10. Goto M., Swanson L.W., Canteras N.S. Connections of the nucleus incertus. J Comp Neurol 2001, 438:86-122.
11. Olucha-Bordonau F.E., Teruel V., Barcia-Gonzalez J., Ruiz-Torner A., Valverde-Navarro A.A., Martinez-Soriano F. Cytoarchitecture and efferent projections of the nucleus incertus of the rat. J Comp Neurol 2003, 464:62-97.
12. Ryan P.J., Ma S., Olucha-Bordonau F.E., Gundlach A.L. Nucleus incertus - an emerging modulatory role in arousal, stress and memory. Neurosci Biobehav Rev 2011, 35:1326-1341.
13. Tanaka M., Iijima N., Miyamoto Y., Fukusumi S., Itoh Y., Ozawa H., et al. Neurons expressing relaxin 3/INSL 7 in the nucleus incertus respond to stress. Eur J Neurosci 2005, 21:1659-1670.
14. Ma S., Bonaventure P., Ferraro T., Shen P.J., Burazin T.C.D., Bathgate R.A.D., et al. Relaxin-3 in GABA projection neurons of nucleus incertus suggests widespread influence on forebrain circuits via G-protein-coupled receptor-135 in the rat. Neuroscience 2007, 144:165-190.
15. Smith C.M., Shen P.J., Banerjee A., Bonaventure P., Ma S., Bathgate R.A.D., et al. Distribution of relaxin 3 and RXFP3 within arousal, stress, affective, and cognitive circuits of mouse brain. J Comp Neurol 2010, 518:4016-4045.
16. Donizetti A., Grossi M., Pariante P., D'Aniello E., Izzo G., Minucci S., et al. Two neuron clusters in the stem of postembryonic zebrafish brain specifically express relaxin-3 gene: first evidence of nucleus incertus in fish. Dev Dyn 2008, 237:3864-3869.
17. Ma S., Sang Q., Lanciego J.L., Gundlach A.L. Localization of relaxin-3 in brain of Macaca fascicularis - identification of nucleus incertus in primate. J Comp Neurol 2009, 517:700-712.
18. Berridge C.W., Schmeichel B.E., España R.A. Noradrenergic modulation of wakefulness/arousal. Sleep Med Rev 2012, 16:187-197.
19. Monti J.M., Jantos H. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog Brain Res 2008, 172:625-646.
20. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nature Rev Neurosci 2007, 8:171-181.
21. Liu C., Eriste E., Sutton S., Chen J., Roland B., Kuei C., et al. Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J Biol Chem 2003, 278:50754-50764.
22. Chen J., Kuei C., Sutton S.W., Bonaventure P., Nepomuceno D., Eriste E., et al. Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species. J Pharmacol Exp Ther 2005, 312:83.
23. Liu C., Kuei C., Sutton S., Shelton J., Zhu J., Nepomuceno D., et al. Probing the functional domains of relaxin-3 and the creation of a selective antagonist for RXFP3/GPCR135 over relaxin receptor RXFP1/LGR7. Ann N Y Acad Sci 2009, 1160:31-37.
24. Wilkinson T.N., Speed T.P., Tregear G.W., Bathgate R.A.D. Evolution of the relaxin-like peptide family. BMC Evol Biol 2005, 5:14.
25. Sutton S.W., Bonaventure P., Kuei C., Roland B., Chen J., Nepomuceno D., et al. Distribution of G-protein-coupled receptor (GPCR) 135 binding sites and receptor mRNA in the rat brain suggests a role for relaxin-3 in neuroendocrine and sensory processing. Neuroendocrinology 2005, 80:298-307.
26. Bathgate R.A.D., Ivell R., Sanborn B.M., Sherwood O.D., Summers R.J. International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol Rev 2006, 58:7-31.
27. Hsu S.Y.T., Nakabayashi K., Nishi S., Kumagai J., Kudo M., Sherwood O.D., et al. Activation of orphan receptors by the hormone relaxin. Science 2002, 295:671-674.
28. Burazin T.C.D., Johnson K.J., Ma S., Bathgate R.A.D., Tregear G.W., Gundlach A.L. Localization of LGR7 (relaxin receptor) mRNA and protein in rat forebrain: correlation with relaxin binding site distribution. Ann N Y Acad Sci 2005, 1041:205-210.
29. 33P]-relaxin binding sites in rat brain: restricted somatic co-expression a clue to relaxin action. Neuroscience 2006, 141:329-344.
30. Smith C.M., Lawrence A.J., Sutton S.W., Gundlach A.L. Behavioral phenotyping of mixed-background (129S5:B6) relaxin-3 knockout mice. Ann N Y Acad Sci 2009, 1160:236-241.
31. Sutton S.W., Shelton J., Smith C., Williams J., Yun S., Motley T., et al. Metabolic and neuroendocrine responses to RXFP3 modulation in the central nervous system. Ann N Y Acad Sci 2009, 1160:242-249.
32. Smith C.M., Hosken I.T., Sutton S.W., Lawrence A.J., Gundlach A.L. Relaxin-3 null mutation mice display a circadian hypoactivity phenotype. Genes Brain Behav 2012, 11:94-104.
33. Watanabe Y., Tsujimura A., Takao K., Nishi K., Ito Y., Yasuhara Y., et al. Relaxin-3-deficient mice showed slight alteration in anxiety-related behavior. Front Behav Neurosci 2011, 5:50.
34. Wolfer D.P., Crusio W.E., Lipp H.P. Knockout mice: simple solutions to the problems of genetic background and flanking genes. Trends Neurosci 2002, 25:336-340.
35. Crusio W.E. Flanking gene and genetic background problems in genetically manipulated mice. Biol Psychiatry 2004, 56:381-385.
36. Kuei C., Sutton S., Bonaventure P., Pudiak C., Shelton J., Zhu J., et al. R3(Bδ23-27) R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7. J Biol Chem 2007, 282:25425-25435.
37. Hossain M.A., Bathgate R.A.D., Rosengren K.J., Shabanpoor F., Zhang S., Lin F., et al. The structural and functional role of the B-chain C-terminal arginine in the relaxin-3 peptide antagonist, R3(Bδ23-27)R/I5. Chem Biol Drug Des 2009, 73:46-52.
38. Shabanpoor F., Akhter Hossain M., Ryan P.J., Belgi A., Layfield S., Kocan M., et al. Minimization of human relaxin-3 leading to high-affinity analogues with increased selectivity for relaxin-family peptide 3 receptor (RXFP3) over RXFP1. J Med Chem 2012, 55:1671-1681.
39. Ganella D.E., Callander G.E., Ma S., Bye C.R., Gundlach A.L., Bathgate R.A.D. Modulation of feeding by chronic rAAV expression of a relaxin-3 peptide agonist in rat hypothalamus. Gene Ther 2013, 20:703-716.
40. Haugaard-Kedström L.M., Shabanpoor F., Hossain M.A., Clark R.J., Ryan P.J., Craik D.J., et al. Design, synthesis and characterization of a single-chain peptide antagonist for the relaxin-3 receptor RXFP3. J Am Chem Soc 2011, 133:4965-4974.
41. Stam N.C., Nithianantharajah J., Howard M.L., Atkin J.D., Cheema S.S., Hannan A.J. Sex-specific behavioural effects of environmental enrichment in a transgenic mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 2008, 28:717-723.
42. Bird M.K., Reid C.A., Chen F., Tan H.O., Petrou S., Lawrence A.J. Cocaine-mediated synaptic potentiation is absent in VTA neurons from mGlu5-deficient mice. Int J Neuropsychopharmacol 2010, 13:133-141.
43. Ralph R.J., Paulus M.P., Geyer M.A. Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice. J Pharmacol Exp Ther 2001, 298:148-155.
44. Sarnyai Z., Sibille E.L., Pavlides C., Fenster R.J., McEwen B.S., Toth M. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc Natl Acad Sci U S A 2000, 97:14731-14736.
45. Bevins R.A., Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat Protoc 2006, 1:1306-1311.
46. Bourin M., Hascoet M. The mouse light/dark box test. Eur J Pharmacol 2003, 463:55-65.
47. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
48. Jud C., Schmutz I., Hampp G., Oster H., Albrecht U. A guideline for analyzing circadian wheel-running behavior in rodents under different lighting conditions. Biol Proced Online 2005, 7:101-116.
49. Bathgate R.A.D., Lin F., Hanson N.F., Otvos L., Guidolin A., Giannakis C., et al. Relaxin-3: improved synthesis strategy and demonstration of its high-affinity interaction with the relaxin receptor LGR7 both in vitro and in vivo. Biochemistry 2006, 45:1043-1053.
50. Sutton S.W., Bonaventure P., Kuei C., Nepomuceno D., Wu J., Zhu J., et al. G-protein-coupled receptor (GPCR)-142 does not contribute to relaxin-3 binding in the mouse brain: further support that relaxin-3 is the physiological ligand for GPCR135. Neuroendocrinology 2006, 82:139-150.
51. Hökfelt T., Bartfai T., Bloom F. Neuropeptides: opportunities for drug discovery. Lancet Neurol 2003, 2:463-472.
52. Novak C.M., Burghardt P.R., Levine J.A. The use of a running wheel to measure activity in rodents: relationship to energy balance, general activity, and reward. Neurosci Biobehav Rev 2012, 36:1001-1014.
53. Hosken I.T., Smith C.M., Chua B.E., Gundlach A.L. Consequences of relaxin-3 null mutation in mice on food-entrainable arousal. Ital J Anat Embryol 2013, 118(Suppl. 1):37-41.
54. Smith C.M., Chua B.E., Zhang C., Walker A.W., Haidar M., Hawkes D., et al. Central injection of relaxin-3 receptor (RXFP3) antagonist peptides reduces motivated food seeking and consumption in C57BL/6J mice. Behav Brain Res 2014, 268:117-126.
55. McGowan B.M., Stanley S.A., White N.E., Spangeus A., Patterson M., Thompson E.L., et al. Hypothalamic mapping of orexigenic action and Fos-like immunoreactivity following relaxin-3 administration in male Wistar rats. Am J Physiol Endocrinol Metab 2007, 292:E913-E919.
56. Watanabe Y., Miyamoto Y., Matsuda T., Tanaka M. Relaxin-3/INSL7 regulates the stress-response system in the rat hypothalamus. J Mol Neurosci 2011, 43:169-174.
57. McGowan B., Minnion J., Murphy K.G., Roy D., Stanley S., Dhillo W.S., et al. Relaxin-3 stimulates the neuroendocrine stress axis via corticotrophin-releasing hormone. J Endocrinol 2014, 221:337-346.
58. Ulrich-Lai Y.M., Herman J.P. Neural regulation of endocrine and autonomic stress responses. Nature Rev Neurosci 2009, 10:397-409.
59. Neufeld-Cohen A., Evans A.K., Getselter D., Spyroglou A., Hill A., Gil S., et al. Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. Mol Psychiatry 2010, 15:426-441. 339.
60. Ryan P.J., Buchler E., Shabanpoor F., Hossain M.A., Wade J.D., Lawrence A.J., et al. Central relaxin-3 receptor (RXFP3) activation decreases anxiety- and depressive-like behaviours in the rat. Behav Brain Res 2013, 244:142-151.
61. Otsubo H., Onaka T., Suzuki H., Katoh A., Ohbuchi T., Todoroki M., et al. Centrally administered relaxin-3 induces Fos expression in the osmosensitive areas in rat brain and facilitates water intake. Peptides 2010, 31:1124-1130.
62. Haugaard-Jonsson L.M., Hossain M.A., Daly N.L., Bathgate R.A.D., Wade J.D., Craik D.J., et al. Structure of the R3/I5 chimeric relaxin peptide, a selective GPCR135 and GPCR142 agonist. J Biol Chem 2008, 283:23811-23818.
63. Hossain M.A., Smith C.M., Ryan P.J., Buchler E., Bathgate R.A.D., Gundlach A.L., et al. Chemical synthesis and orexigenic activity of rat/mouse relaxin-3. Amino Acids 2013, 44:1529-1536.
64. Alvarez-Jaimes L., Sutton S.W., Nepomuceno D., Motley S.T., Cik M., Stocking E., et al. In vitro pharmacological characterization of RXFP3 allosterism: an example of probe dependency. PLoS ONE 2012, 7:e30792.
65. McNaughton N., Gray J.A. Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. J Affect Disord 2000, 61:161-176.
66. Pfaff D., Ribeiro A., Matthews J., Kow L.M. Concepts and mechanisms of generalized central nervous system arousal. Ann N Y Acad Sci 2008, 1129:11-25.
67. Kohlmeier K.A., Tyler C.J., Kalogiannis M., Ishibashi M., Kristensen M.P., Gumenchuk I., et al. Differential actions of orexin receptors in brainstem cholinergic and monoaminergic neurons revealed by receptor knockouts: implications for orexinergic signaling in arousal and narcolepsy. Front Neurosci 2013, 7:246.